IN BRIEF: Haleon acquires remaining 12% stake in Chinese joint venture
Haleon PLC - Weybridge, Surrey-based consumer healthcare firm that spun out of GSK PLC in 2022 - Agrees to acquire the remaining 12% stake in Tianjin TSKF Pharmaceutical Co Ltd, its joint venture in China, following its acquisition of a further 33% interest in December 2024. The remaining stake will be bought from partner Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd for a total of CNY1.62 billion, around USD221 million. TSKF will become a wholly-owned subsidiary of Haleon. Read More